63152-60-3

Basic information

• Product Name: 1-(tert-butylamino)-3-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]propan-2-ol
• CAS NO: 63152-60-3
• Molecular Formula: C₁₅H₂₂N₂O₃
• Molecular Weight: 278.3468
• Mol File: 63152-60-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 445.6°C at 760 mmHg
• Flash Point: 223.3°C
• Density: 1.133g/cm³
• Vapor Pressure: 1E-08mmHg at 25°C
• Refractive Index: 1.555
• CAS DataBase Reference: 1-(tert-butylamino)-3-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(tert-butylamino)-3-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]propan-2-ol(63152-60-3)
• EPA Substance Registry System: 1-(tert-butylamino)-3-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]propan-2-ol(63152-60-3)

Safety Data

• Hazardous Substances Data: 63152-60-3(Hazardous Substances Data)

Usage

General Description

1-(tert-butylamino)-3-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]propan-2-ol is a chemical compound commonly used in the pharmaceutical industry. It is a beta-adrenergic agonist that works by relaxing the muscles in the airways and making it easier to breathe. 1-(tert-butylamino)-3-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]propan-2-ol is often used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its molecular structure includes a tert-butyl group, an aminomethyl group, and a benzisoxazol group, which contribute to its pharmacological properties. This chemical has demonstrated potential as an effective bronchodilator and is under ongoing research for further therapeutic applications.

Upstream product

• 51110-58-8 3-Methyl-4-hydroxy-1,2-benzisoxazol 
• 63152-87-4 1-(3-Methyl-1,2-benzisoxazol-4-yl-oxy)-2,3-epoxypropan 
• 75-64-9 tert-butylamine 

Relevant articles and documents

New beta-sympatholytic agents. Synthesis and pharmacological activity of isomeric benzthiazole and benzoxazole derivates (author's transl)

The synthesis and comparative pharmacological studies concerning structure-activity relationship of new benzothiazole, benzisothiazole, benzoxazole, and benisoxazole derivatives with beta-sympatholytic activity are reported. Most of the 4-benzisothiazole derivatives studied strongly act on cardiac beta 1-receptors in rats in situ (2.6-8.3 times propranolol). On the other hand derivatives of 4-benzisoxazole and 5-benzisothiazole are less potent. A strong decrease in activity was observed going from the benzisothiazoles and benzisoxazoles to the isomeric benzthiazoles and benzoxazoles. The active substances also block vascular beta 2-receptors. In the most cases they have little intrinsic adrenergic activity. The observed tendency concerning beta 1-selectivity in rats could not be confirmed in cats. The most potent 4-benzisothiazole derivatives in rats show also - beside some minor differences - very good beta-sympatholytic activity in cats after i.v. as well as after i.d. administration. Similar to the results in rats and cats the 4-(2-hydroxy-3-isopropylamino-propoxy)-1,2-benzisothiazole (LU 24329) was found to possess a high activity in conscious dogs by oral or i.v. application. Both in dogs (i.v.) and in isolated perfused guinea pig hearts LU 24329 is eleven times more active than propranolol in blocking beta 1-receptors. A negative inotropic effect as an expression of non-specific membrane-stabilizing action of LU 24329 is also demonstrated in guinea pig hearts. The effective concentration is 4650 times higher than that effective on beta 1-adrenoceptors. The active compounds have a moderate acute toxicity. The LD50 values in mice after i.p. administration are ranging from 55-174% of the propranolol toxicity.